

Lipum AB announces the Nomination Committee for the 2024 Annual General Meeting

Lipum AB (publ) ("Lipum") announces its Nomination Committee for the Annual General Meeting 2024. In accordance with the decision at the Annual General Meeting, the three largest shareholders in terms of voting rights on 1 September 2023 have appointed a Nomination Committee for the Annual General Meeting 2024.

Pursuant to the resolution of the Annual General Meeting, the largest shareholders in terms of voting rights have appointed a Nomination Committee for the 2024 Annual General Meeting.

The largest shareholders in terms of voting rights (considering ownership groups) as of 1 September 2023 were Flerie Invest AB represented by Cecilia Edström, Christian von Koenigsegg with companies, Adam Dahlberg representing the family and the Crafoord Foundation, and the founders represented by Olle Hernell. These ownership constellations have each appointed a member, as described below, to constitute Lipum's Nomination Committee together with the chairman of the board.

Cecilia Edström (Chairman)

Adam Dahlberg (also represents Christian von Koenigsegg and companies)

Olle Hernell

Ulf Björklund, Chairman of the Board of Lipum AB (publ)

The shareholders who have appointed members to the Nomination Committee together represent approximately 68 percent of the voting rights of all shares in the company.

Shareholders are welcome to submit proposals and views to the Nomination Committee via email to ir@lipum.se. To ensure that proposals can be considered, these must be received in good time before the annual general meeting, but no later than 29 February 2024.

Contacts

Ola Sandborgh, CEO

ola.sandborgh@lipum.se

+46 72 218 80 21

Web: www.lipum.se

PRESS RELEASE

18 December 2023 11:30:00 CET

**About Us**

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments

[Lipum AB announces the Nomination Committee for the 2024 Annual General Meeting](#)